Table 4.

Central macular thickness (μm) before and after intravitreal injection.

	Treated eye	Fellow eye	p valuea
IVR group
Baseline	450.55 ± 131.30	257.10 ± 27.94	< 0.001*
Third month	309.00 ± 81.06	265.68 ± 37.03	0.010*
Sixth month	338.66 ± 105.32	255.11 ± 28.35	< 0.001*
Twelfth month	333.42 ± 102.93	257.92 ± 35.34	0.004*
p valueb	< 0.001*	0.848
IVA group
Baseline	436.21 ± 163.89	257.45 ± 24.42	< 0.001*
Third month	275.69 ± 74.47	257.28 ± 22.91	0.910
Sixth month	307.28 ± 92.59	257.64 ± 21.66	0.010*
Twelfth month	311.86 ± 118.29	255.20 ± 21.57	0.012*
p valueb	< 0.001*	0.312

IVR, group that received intravitreal ranibizumab injection; IVA, group that received intravitreal aflibercept injection.

^aComparison between the treated and fellow eyes during each period (Mann–Whitney U-test).

^bComparison between the baseline and twelfth month for each value (Wilcoxon signed-rank test).

* p <.05.